POG 8625: A randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with stages I, IIA, IIIA 1 Hodgkin disease: A report from the children's oncology group

Journal of Pediatric Hematology/Oncology

Volumn 28, Issue 6, 2006, Pages 362-368

  Kung, Faith H ^a,j   Schwartz, Cindy L ^b   Ferree, Carolyn R ^c   London, Wendy B ^d,e   Ternberg, Jessie L ^f   Behm, Fred G ^g   Wharam, Moody D ^h   Falletta, John M ⁱ   De Alarcon, Pedro ^g   Chauvenet, Allen R ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BROWN UNIVERSITY   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e COG Grant U10 ^*  (United States)

^f Washington University Medical School   (United States)

^g UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^h NATIONAL CANCER INSTITUTE   (United States)

ⁱ DUKE UNIVERSITY MEDICAL CENTER   (United States)

^j UCSD MEDICAL CENTER   (United States)

more..

Author keywords

Chemotherapy versus chemoradiotherapy; Children; Hodgkin disease

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; IMIDAZOLECARBOXAMIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE SULFATE;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; MALE; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MECHLORETHAMINE; NEOPLASM STAGING; PREDNISONE; PROCARBAZINE; REMISSION INDUCTION; VINBLASTINE; VINCRISTINE;

EID: 33745677279     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/00043426-200606000-00008     Document Type: Article

References (39)

1. Peters M. A study of survival in Hodgkin's disease treated radiologically. Am J Roentgenol. 1950;63:299-311.
2. Cornbleet MA, Vitolo U, Ultmann JE, et al. Pathologic stages IA and IIA Hodgkin's disease: results of treatment with radiotherapy alone (1968-1980). J Clin Oncol. 1985;3:758-768.
3. Hoppe RT, Coleman CN, Cox RS, et al. The management of stage I-II Hodgkin's disease with irradiation alone or combined modality therapy: the Stanford experience. Blood. 1982;59:455-465.
4. Kaplan HS. The radical radiotherapy of regionally localized Hodgkin's disease. Radiology. 1962;78:553-561.
5. Young RC, DeVita VT, Johnson RE. Hodgkin's disease in childhood. Blood. 1973;42:163-174.
6. Devita VT Jr, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med. 1970;73:881-895.
7. Longo DL, Glatstein E, Duffey PL, et al. Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: seven-year results of a prospective randomized trial. J Clin Oncol. 1991;9:906-917.
8. Madanat FF. MOPP therapy in children with Hodgkin's disease. Am J Pediatr Hematol Oncol. 1989;11:407-410.
9. Olweny CL, Katongole-Mbidde E, Kiire C, et al. Childhood Hodgkin's disease in Uganda: a ten year experience. Cancer. 1978;42:787-792.
10. Donaldson SS, Link MP. Combined modality treatment with low-dose radiation and MOPP chemotherapy for children with Hodgkin's disease. J Clin Oncol. 1987;5:742-749.
11. Gehan EA, Sullivan MP, Fuller LM, et al. The intergroup Hodgkin's disease in children. A study of stages I and II. Cancer. 1990;65:1429-1437.
12. Jenkin D, Chan H, Freedman M, et al. Hodgkin's disease in children: treatment results with MOPP and low-dose, extended-field irradiation. Cancer Treat Rep. 1982;66:949-959.
13. Bonadonna G. Chemotherapy strategies to improve the control of Hodgkin's disease: the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 1982;42:4309-4320.
14. Rueda A, Alba E, Ribelles N, et al. Six cycles of ABVD in the treatment of stage I and II Hodgkin's lymphoma: a pilot study. J Clin Oncol. 1997;15:1118-1122.
15. Oberlin O, Leverger G, Pacquement H, et al. Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin's disease: the experience of the French Society of Pediatric Oncology. J Clin Oncol. 1992;10:1602-1608.
16. Vecchi V, Pileri S, Burnelli R, et al. Treatment of pediatric Hodgkin disease tailored to stage, mediastinal mass, and age. An Italian (AIEOP) multicenter study on 215 patients. Cancer. 1993;72:2049-2057.
17. Donaldson SS, Hudson MM, Lamborn KR, et al. VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodakin's disease: results of a prospective clinical trial. J Clin Oncol. 2002;20:3081-3087.
18. Nachman JB, Sposto R, Herzog P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol. 2002;20:3765-3771.
19. Schellong G, Potter R, Bramswig J, et al. High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group. J Clin Oncol. 1999;17:3736-3744.
20. Hunger SP, Link MP, Donaldson SS. ABVD/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin's disease: the Stanford experience. J Clin Oncol. 1994;12:2160-2166.
21. Khan SP, Gilchrist GS, Arndt CA, et al. Vancouver hybrid: preliminary experience in the treatment of Hodgkin's disease in childhood and adolescence. Mayo Clin Proc. 1994;69:949-954.
22. Lobo-Sanahuja F, Garcia I, Barrantes JC, et al. Pediatric Hodgkin's disease in Costa Rica: twelve years' experience of primary treatment by chemotherapy alone, without staging laparotomy. Med Pediatr Oncol. 1994;22:398-403.
23. Riihl U, Albrecht M, Dieckmann K, et al. Response-adapted radiotherapy in the treatment of pediatric Hodgkin's disease: an interim report at 5 years of the German GPOH-HD 95 trial. Int J Radiat Oncol Biol Phys. 2001;51:1209-1218.
24. Kaplan E. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
25. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. JRSSA. 1972;135:185-198.
26. Savage I. Contributions to the theory of rank order statistics - the two sample case. Am Math Stat. 1956;27:590-615.
27. Andrieu JM, Dana M, Desprez-Curely JP, et al. MOPP chemotherapy plus irradiation for Hodgkin's disease, stages IA to IIIB. Long-term results of the prospective trial H72 (1972-1976, 334 patients). Hematol Oncol. 1985;3:219-231.
28. Cramer P, Andrieu JM. Hodgkin's disease in childhood and adolescence: results of chemotherapy-radiotherapy in clinical stages IA-IIB. J Clin Oncol. 1985;3:1495-1502.
29. Diehl V, Pfreundschuh M, Loffler M, et al. Chemotherapy of Hodgkin's lymphoma with alternating cycles of COPP (cyclophosphamide, vincristin, procarbazine, prednisone) and ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine). Results of the HD1 and HD3 trials of the German Hodgkin Study Group. Med Oncol Tumor Pharmacother. 1989;6:155-162.
30. Glimelius B, Kalkner M, Enblad G, et al. Treatment of early and intermediate stages of supradiaphragmatic Hodgkin's disease: the Swedish National Care Programme experience. Swedish Lymphoma Study Group. Ann Oncol. 1994;5:809-816.
31. Marcus KC, Kalish LA, Coleman CN, et al. Improved survival in patients with limited stage IIIA Hodgkin's disease treated with combined radiation therapy and chemotherapy. J Clin Oncol. 1994;12:2567-2572.
32. Rosenthal J, Ben Arush MW, Kuten A, et al. Hodgkin's disease in childhood: treatment modalities, outcome and epidemiological aspects. The Northern Israel Cancer Center experience. Am J Pediatr Hematol Oncol. 1994;16:138-142.
33. Schellong G, Bramswig JH, Hornig-Franz I. Treatment of children with Hodgkin's disease-results of the German Pediatric Oncology Group. Ann Oncol. 1992;3(Suppl 4):73-76.
34. Levi JA, Wiernik PH, O'Connel MJ. Patterns of relapse in stages I, II and IIIA Hodgkin's disease: influence of initial therapy and implications for the future. Int J Radiat Oncol Biol Phys. 1977;2:853-862.
35. Leslie NT, Mauch PM, Hellman S. Stage IA to IIB supradiaphragmatic Hodgkin's disease. Long-term survival and relapse frequency. Cancer. 1985;55(Suppl 9):2072-2078.
36. Timothy A, Van Dyk J, Sutcliffe SB, et al. Hodgkin's Disease. Oxford: Blackwell Science; 1987.
37. Zinzani PL, Mazza P, Gherlinzoni F, et al. Massive mediastinal involvement in stage I-II Hodgkin's disease: response to combined modality treatment. Leuk Lymphoma. 1992;8:81-85.
38. Weiner MA, Leventhal B, Brecher ML, et al. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group Study. J Clin Oncol. 1997;15:2769-2779.
39. Schwartz C, Tebbi C, Constine LS, et al. Response based therapy for pediatric Hodgkin disease: Pediatric Oncology Group (POG) Protocols 9425/9426. Med Pediatr Oncol. 2001;37:263.